QUALITY OF HERBAL REMEDIES
|
|
- Julian Lane
- 5 years ago
- Views:
Transcription
1 QUALITY OF HERBAL REMEDIES Guideline Title Quality of Herbal Remedies Legislative basis Directive 75/318/EEC as amended Date of first adoption November 1988 Date of entry into May 1989 force Status Last revised 1988 Previous titles/other None references Additional Notes This note for guidance concerns the application to herbal based remedies of Part 2 of the Annex to Directive 75/318/EEC as amended, with a view to the granting of a marketing authorisation for a medicinal product. CONTENTS A QUALITATIVE AND QUANTITATIVE PARTICULARS OF THE CONSTITUENTS B DESCRIPTION OF THE METHOD OF PREPARATION C CONTROL OF STARTING MATERIALS D CONTROL OF TESTS CARRIED OUT AT AN INTERMEDIATE STAGE OF THE MANUFACTURING PROCESS OF THE FINISHED PRODUCT E CONTROL TESTS ON FINISHED PRODUCT F STABILITY TESTS ANNEX 195
2 QUALITY OF HERBAL REMEDIES Note for guidance concerning the application of Part 2 of the Annex to Directive 75/318/EEC as amended. The special problems of herbal remedies and the differences between medicinal products containing chemically defined active substances are described in this note for guidance. Consistent quality for products of vegetable origin can only be assured if the starting materials are defined in a rigorous and detailed manner including especially the specific botanical identification of the plant material used. It is also important to know the geographical source and the conditions under which the vegetable substance is obtained to ensure material of consistent quality. Reference substances used in the control of all stages of the manufacturing process should be clearly defined. A QUALITATIVE AND QUANTITATIVE PARTICULARS OF THE CONSTITUENTS 1. In the case of a vegetable substance either a) the quantity of vegetable substance must be stated or b) the quantity of a vegetable substance may be given as a range corresponding to a defined quantity of constituents with known therapeutic activity. EXAMPLE a) Active substance 900 mg or b) Active substance mg, corresponding to 25 mg of hydroxyanthracene glycosides, calculated as Sennoside B Other substance mg, corresponding to the quantity of Sennae folium 197
3 3AQ22a 2. In the case of a vegetable substance preparation either a) the equivalent quantity, or the ratio e.g. 8:1 of the vegetable substance to the vegetable substance preparation must be stated (this does not apply to fatty or essentials oils). or b) the quantity of the vegetable substance preparation may be given as a range corresponding to a defined quantity of constituents with know therapeutic activity (see example). The composition of any solvent or solvent mixture and the physical state of the extract must be indicated. If any other substance is added during the manufacture of the vegetable substance preparation to adjust the vegetable substance preparation to a certain level of constituents with known therapeutic activity, or for any other purpose, the added substance must be mentioned as an other substance and the genuine extract as the active substance. EXAMPLE a) Active substance 125 mg dry 60% ethanolic extract (8:1) or 125 mg equivalent to 1000 mg dry 60% ethanolic extract or b) Active substance dry 60% ethanolic extract (8:1) mg, corresponding to 25 mg of hydroxyanthracene glycosides, calculated as Sennoside B Other substances Dextrin mg 198
4 B DESCRIPTION OF THE METHOD OF PREPARATION The manufacturing process within the meaning of this section is the preparation of the finished product from the starting materials. The description should include details of any comminution or size reduction step, and details of any process such as fumigation etc. used to reduce the levels of microbial contamination together with the controls exercised over the process. If vegetable substance preparations are the starting material, the manufacture of the vegetable substance preparations and their controls do not belong under this section but under section C. C CONTROL OF STARTING MATERIALS 1. Control of the vegetable substance A complete monograph for each vegetable substance must be submitted, even if the starting material is a vegetable substance preparation. This also applies if the applicant is not the manufacturer of the preparation. In the case of fatty or essential oils a complete monograph for the vegetable substance is not required, only the scientific name of the parent plant and its part(s) have to be stated. If no monograph for the vegetable substance is given in a Pharmacopoeia referred to i n Directive 75/318/EEC as amended, Annex 1, a monograph on the vegetable substance must be supplied and should be set out in the same way where practicable, as the monographs on vegetable substances in the European Pharmacopoeia. This should include the botanical name and authority and the common name if used for labelling purposes. Information on the site of collection, the time of harvesting and stage of growth, treatment during growth with pesticides etc., and drying and storage conditions should be included if possible. The monograph should be established on the basis of recent scientific data. In the case of vegetable substances with constituents of known therapeutic activity, assays of their content (with test procedure) are required. The content must be included as a range, so as to ensure reproducibility of the quality of the finished product. As a general rule, vegetable substances must be tested for microbiological quality and for residues of pesticides and fumigation agents, radioactivity, toxic metals, likely contaminants and adulterants, etc., unless otherwise justified. Specifications and descriptions of the analytical procedures must be submitted, together with the limits applied. Reference samples of the vegetable substances must be available for use in comparative tests e.g. macro and microscopic examination, chromatography etc. 2. Control of vegetable substance preparations If the herbal remedy contains not the vegetable substance itself but a preparation, the monograph on the substance must be followed by a description and validation of the manufacturing process for the vegetable substance preparation. For each vegetable substance preparation, a monograph must be submitted. This must be established on the basis of recent scientific data and must give particulars of the characteristics, identification tests and purity tests. This has to be done e.g. by different appropriate chromatographic methods. If deemed necessary by the results of the analysis of the starting material, tests on microbiological quality, residues of pesticides, fumigation 199
5 3AQ22a agents, radioactivity, solvents and toxic metals have to be carried out. Quantitative determination (assay) of characteristic constituents is required. The content must be indicated with the lowest possible tolerance. The test methods must be described in detail. If preparations from vegetable substances with constituents with known therapeutic activity are standardised (i.e. adjusted to a certain level of constituents with known therapeutic activity) it must be stated how such standardisation is achieved. If another substance is used for this purpose, it is necessary to specify as a range the quantity that can be added. D CONTROL OF TESTS CARRIED OUT AT AN INTERMEDIATE STAGE OF THE MANUFACTURING PROCESS OF THE FINISHED PRODUCT Details of all control tests with details of test procedures and limits applied at any intermediate stages of the manufacturing processes are required, especially if these tests cannot be done in the finished product. E CONTROL TESTS ON FINISHED PRODUCT The control tests on the finished product must be such as to allow the qualitative and quantitative determination of the composition of the active substances and a specification has to be given which may be done by using markers if constituents with known therapeutic activity are unknown. In the case of vegetable substances or vegetable substance preparations with constituents of known therapeutic activity, these constituents must also be specified and quantitatively determined. If a herbal remedy contains several vegetable substances or preparations of several vegetable substances and it is not possible to perform a quantitative determination of each active substance, the determination may be carried out jointly for several active substances. The need for this procedure must be justified. F STABILITY TESTS Since the vegetable substance or vegetable substance preparation in its entirety is regarded as the active substance, a mere determination of the stability of the constituents with known therapeutic activity will not suffice. It must also be shown, as far as possible e.g. by means of appropriate fingerprint chromatograms, that other substances present in the vegetable substance or in the vegetable substance preparation are likewise stable and that their proportional content remains constant. If a herbal remedy contains several vegetable substances or preparations of several vegetable substances and if it is not possible to determine the stability of each active substance, the stability of the medicinal product should be determined by appropriate fingerprint chromatograms, appropriate overall methods of assay and physical and sensory tests or other appropriate tests. If the only evidence that can be submitted concerning the stability of the finished product consists of results of trials in which each active substance was separately tested in a 200
6 formulation corresponding to that of the finished product, the reasons why it is not possible to carry out stability tests on the finished product must be stated in full. It must furthermore be shown that interactions between the active substances and the excipients in the finished product are unlikely to occur. 201
7 3AQ22a ANNEX Glossary Herbal remedies (herbal medicines) are medicinal products containing as active substances exclusively plant material and/or vegetable substance preparations. Vegetable substances are plant material used for a medicinal purpose. A vegetable substance or a preparation thereof is regarded as one active substance in its entirety whether or not the constituents with therapeutic activity are known. Vegetable substance preparations are comminuted or powdered vegetable substances, extracts, tinctures, fatty or essential oils, expressed juices etc. prepared from vegetable substances, and preparations whose production involves a fractionation, purification or concentration process. However, chemically defined isolated constituents or their mixtures are not vegetable substance preparations. Other substances such as solvents, diluents, preservatives may form part of vegetable substance preparations. These substances must be indicated. Constituents with known therapeutic activity are chemically defined substances or groups of substances which are known to contribute to the therapeutic activity of a vegetable substance or of a preparation. Markers are chemically defined constituents of a vegetable substance which are of interest for control purposes. Markers may serve to calculate the quantity of vegetable substance or preparation in the finished product if that marker has been quantitatively determined in the vegetable substance or preparation when the starting materials were tested. 202
Guideline on quality of herbal medicinal products 1 /traditional herbal medicinal products
31 March 2011 Committee for Medicinal Products for Human Use (CHMP) Committee for Medicinal Products for Veterinary Use (CVMP) Committee on Herbal Medicinal Products (HMPC) Guideline on quality of herbal
More informationGuideline on quality of herbal medicinal products 2 /traditional herbal medicinal products
1 2 3 4 5 05 June 2018 EMA/HMPC/201116/2005 1 Rev. 3 Committee on Herbal Medicinal Products (HMPC) Guideline on quality of herbal medicinal products 2 /traditional herbal medicinal products DRAFT Revision
More informationGood pharmacopoeial practices: Chapter on monographs on herbal medicines
Annex 7 Good pharmacopoeial practices: Chapter on monographs on herbal medicines Background Following the fiftieth meeting of the WHO Expert Committee on Specifications for Pharmaceutical Preparations,
More informationH e r b a l M e dicines' Q U A L I T Y M ANUAL. I. Introduction
INTRODUCTION To the Recommendation by the Board of the Eurasian Economic Commission Dated 20 No H e r b a l M e dicines' Q U A L I T Y M ANUAL I. Introduction 1. The Herbal Medicines Quality Manual (hereinafter
More informationEUROPEAN COMMISSION ENTERPRISE AND INDUSTRY DIRECTORATE-GENERAL. EudraLex The Rules Governing Medicinal Products in the European Union
EUROPEAN COMMISSION ENTERPRISE AND INDUSTRY DIRECTORATE-GENERAL Consumer goods Pharmaceuticals Brussels, 16 March 2006 EudraLex The Rules Governing Medicinal Products in the European Union Volume 4 EU
More informationQUALITY OF HERBAL MEDICINAL PRODUCTS: PRESENT REQUIREMENTS
QUALITY OF HERBAL MEDICINAL PRODUCTS: PRESENT REQUIREMENTS Phytopharm 2015 Bonn, 21 24 July 2015 1 Dr. Barbara Steinhoff Bundesverband der Arzneimittel-Hersteller CONTENTS Production of herbal starting
More informationAD HOC WORKING GROUP ON HERBAL MEDICINAL PRODUCTS
The European Agency for the Evaluation of Medicinal Products Evaluation of Medicines for Human Use 28 January 1999 EMEA/HMPWP/16/99 AD HOC WORKING GROUP ON HERBAL MEDICINAL PRODUCTS Final Comments for
More informationEUROPEAN COMMISSION ENTERPRISE AND INDUSTRY DIRECTORATE-GENERAL. EudraLex The Rules Governing Medicinal Products in the European Union
EUROPEAN COMMISSION ENTERPRISE AND INDUSTRY DIRECTORATE-GENERAL Consumer goods Pharmaceuticals Brussels, 01 September 2008 EudraLex The Rules Governing Medicinal Products in the European Union Volume 4
More informationDiscussion at the HMPC January March Draft agreed by Quality Working Party April Adoption by CHMP for release for consultation 26 May 2005
1 2 3 4 5 05 June 2018 EMA/HMPC/162241/2005 1 Rev. 3 6 7 8 9 Guideline on specifications: test procedures and acceptance criteria for herbal substances 2, herbal preparations 3 and herbal 4 /traditional
More information2. Selection criteria for substances of herbal origin relevant for standardization and quality control of herbal medicines 77
Annex 1 WHO guidelines for selecting marker substances of herbal origin for quality control of herbal medicines 1. Introduction 72 1.1 Background 72 1.1.1 Preparation of the document 73 1.2 Objectives
More informationScientific and Regulatory Basis for Development, Quality Assurance and Marketing Authorisation
Scientific and Regulatory Basis for Development, Quality Assurance and Marketing Authorisation Dr. Frauke Gaedcke, Waidesch Dr. Barbara Steinhoff, Konigswinter In collaboration with Dr. Helga Blasius,
More informationDiscussion by HMPC Drafting Group on Quality February Start of public consultation 27 June 2012
1 2 3 22 May 2012 EMA/HMPC/312890/2012 Committee on Herbal Medicinal Products (HMPC) 4 5 6 7 8 Concept paper on non-pharmacopoeial reference standards for herbal substances, herbal preparations and herbal
More informationDiscussion by HMPC Drafting Group on Quality September Start of public consultation 15 February 2013
1 2 3 15 January 2013 EMA/HMPC/13658/2013 Committee on Herbal Medicinal Products (HMPC) 4 5 6 7 Concept paper on use of recovered/recycled solvents in the manufacture of herbal preparations for use in
More informationDIRECTIVE 2004/24/EC OF THE EUROPEAN PARLIAMENT AND OF THE COUNCIL. of 31 March 2004
30.4.2004 Official Journal of the European Union L 136/85 DIRECTIVE 2004/24/EC OF THE EUROPEAN PARLIAMENT AND OF THE COUNCIL of 31 March 2004 amending, as regards traditional herbal medicinal products,
More informationQuestions & answers on quality of herbal medicinal products/traditional herbal medicinal products 1
12 August 2014 EMA/HMPC/41500/2010 Rev.4 Committee on Herbal Medicinal Products (HMPC) Questions & answers on quality of herbal medicinal products/traditional herbal medicinal products 1 Table of content
More informationGuideline on the use of the CTD format in the preparation of a registration application for traditional herbal medicinal products 1
1 2 3 8 August 2012 EMA/HMPC/71049/2007 Rev. 1 Committee on Herbal Medicinal Products (HMPC) 4 5 6 7 Guideline on the use of the CTD format in the preparation of a registration application for traditional
More informationEuropean Medicines Agency COMMITTEE ON HERBAL MEDICINAL PRODUCTS (HMPC) FINAL
European Medicines Agency London, 12 November 2009 Doc. Ref. EMEA/HMPC/67644/2009 COMMITTEE ON HERBAL MEDICINAL PRODUCTS (HMPC) FINAL GUIDELINE ON SELECTION OF TEST MATERIALS FOR GENOTOXICITY TESTING FOR
More informationHERBAL MEDICINES: Product Licence To Traditional Herbal Registration in the UK. Presented by: Mariam Aslam
HERBAL MEDICINES: Product Licence To Traditional Herbal Registration in the UK Presented by: Mariam Aslam ESCOP European Scientific Cooperative On Phytotheapy (ESCOP) Founded in June 1989 as an umbrella
More informationREPORT FROM THE AD HOC WORKING GROUP ON HERBAL MEDICINAL PRODUCTS 1997/1998
The European Agency for the Evaluation of Medicinal Products Evaluation of Medicines for Human Use REPORT FROM THE AD HOC WORKING GROUP ON HERBAL MEDICINAL PRODUCTS 1997/1998 The views presented in this
More informationDecision tree for the safety assessment of botanical cosmetic ingredients. Personal Care Products Council CIR Science and Support Committee
Decision tree for the safety assessment of botanical cosmetic ingredients Personal Care Products Council CIR Science and Support Committee Using the Decision Tree Provided as a guidance tool for finished
More informationDirection générale Médicaments
Unité Homéopathie & Plantes Coordinatrice de Marie-Anne Mouyart l unité : Notre référence: Date: SPF Santé publique, Sécurité de la Chaîne alimentaire et Environnement DGM/WV/1 18/10/2004 Direction générale
More informationREGULATION concerning Marketing Authorisations for Natural Medicinal Products and Registration of Traditional Herbal Medicinal Products, No. 142/2011.
REGULATION concerning Marketing Authorisations for Natural Medicinal Products and Registration of Traditional Herbal Medicinal Products, No. 142/2011. CHAPTER I Scope and definitions. Article 1 Scope.
More informationGuideline on the use of the CTD format in the preparation of a registration application for traditional herbal medicinal products 1
5 April 2016 EMA/HMPC/71049/2007 Rev. 2 Committee on Herbal Medicinal Products (HMPC) Guideline on the use of the CTD format in the preparation of a registration application for traditional herbal medicinal
More informationWHO guidelines on good manufacturing practices (GMP) for herbal medicines
WHO guidelines on good manufacturing practices (GMP) for herbal medicines Contents Contents Acknowledgements...v Preface...vii Section I...1 WHO good manufacturing practices (GMP): updated supplementary
More informationEuropean Medicines Agency Inspections
European Medicines Agency Inspections London, 9 June 2006 Doc. Ref. EMEA/CHMP/CVMP/QWP/40728/2006 OVERVIEW OF COMMENTS RECEIVED ON DRAFT GUIDELINE GUIDELINE ON SPECIFICATIONS: TEST PROCEDURES AND ACCEPTANCE
More informationHOMEOPATHIC MEDICINAL PRODUCT WORKING GROUP (HMPWG)
HOMEOPATHIC MEDICINAL PRODUCT WORKING GROUP (HMPWG) POINTS TO CONSIDER ON NON-CLINICAL SAFETY OF HOMEOPATHIC MEDICINAL PRODUCTS OF BOTANICAL, MINERAL AND CHEMICAL ORIGIN DISCUSSION IN THE HMPWG April 2002
More informationHOMEOPATHIC MEDICINAL PRODUCT WORKING GROUP (HMPWG) DRAFT (12/08) POINTS TO CONSIDER ON STABILITY TESTING OF HOMEOPATHIC MEDICINAL PRODUCTS
HOMEOPATHIC MEDICINAL PRODUCT WORKING GROUP (HMPWG) DRAFT (12/08) POINTS TO CONSIDER ON STABILITY TESTING OF HOMEOPATHIC MEDICINAL PRODUCTS DISCUSSION IN THE SUBGROUP STABILITY April / May 2008 DISCUSSION
More informationEuropean Union legislation on Food additives, Food enzymes, Extractions solvents and Food flavourings
European Union legislation on Food additives, Food enzymes, Extractions solvents and Food flavourings European Commission, DG, Unit E3 Chemicals, contaminants and pesticides Serbia-Screening meeting on
More informationGOOD PHARMACOPOEIAL PRACTICES Draft chapter on monographs on herbal medicines
7 September 2017 Draft 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 GOOD PHARMACOPOEIAL PRACTICES Draft chapter on monographs on herbal medicines
More informationWholistic Approach to Herbal Products Quality Case Study: Thyme
Wholistic Approach to Herbal Products Quality Case Study: Thyme Adnan Badwan, Hashim Taha and Nadia Abu Nimeh Delass Natural Products Company, Naor-Jordan The First International Conference on Natural
More informationGeneral Concepts in the European Pharmacopoeia. Anne-Sophie Bouin European Pharmacopoeia Department, EDQM, Council of Europe
General Concepts in the European Pharmacopoeia Anne-Sophie Bouin European Pharmacopoeia Department, EDQM, Council of Europe General notices Anne-Sophie Bouin, 28/10/09 2009 EDQM, Council of Europe, All
More informationPublic Assessment Report Scientific discussion
Public Assessment Report Scientific discussion Cynaramin, oral drops, solution (Peumus boldus Molina, folium, liquid extract, (1:10); Taraxacum officinale Web., radix and herba, liquid extract, (1:17))
More informationEMEA WORKING PARTY ON HERBAL MEDICINAL PRODUCTS
The European Agency for the Evaluation of Medicinal Products Evaluation of Medicines for Human Use 25 October 1999 EMEA/HMPWP/23/99 EMEA WORKING PARTY ON HERBAL MEDICINAL PRODUCTS UPDATED DRAFT POINTS
More informationDepartment of Pharmaceutical Sciences, University of Antwerp, Antwerp, Belgium
Review 683 Legal Requirements for the Quality of Herbal Substances and Herbal Preparations for the Manufacturing of Herbal Medicinal Products in the European Union* Authors Affiliation Arnold Vlietinck,
More informationCOMMITTEE ON HERBAL MEDICINAL PRODUCTS (HMPC) FINAL PROCEDURE FOR THE PREPARATION OF COMMUNITY MONOGRAPHS FOR TRADITIONAL HERBAL MEDICINAL PRODUCTS
European Medicines Agency Evaluation of Medicines for Human Use London, 11 January 2007 Ref: EMEA/HMPC/182320/2005 Rev. 2 COMMITTEE ON HERBAL MEDICINAL PRODUCTS (HMPC) FINAL PROCEDURE FOR THE PREPARATION
More informationQuality Control of Herbal Products. Dr. Fabio Boylan
Quality Control of Herbal Products Quality Control of Herbal Products Known X Unknown Different strategies Quality Control of Herbal Products Single X Multiple Different strategies Quality Control of Herbal
More informationDraft agreed by HMPC Quality Drafting Group October Adopted by HMPC 12 November 2013
3 December 2013 EMA/HMPC/453258/2013 Committee on Herbal Medicinal Products (HMPC) Reflection paper on the use of recovered/recycled solvents in the manufacture of herbal preparations for use in herbal
More informationSHRI GURU RAM RAI INSTITUTE OF TECHNOLOGY AND SCIENCE
STANDARDIZATION OF HERBAL PRODUCTS Herbal drug, the naturally of mankind since ages in combating various diseases has received a raw deal from the practitioners of the modern medicine due to many reasons.
More informationDormeasan, oral drops, solution (Valeriana officinalis L., radix, tincture; Humulus lupulus L., strobulus, tincture)
Public Assessment Report Scientific discussion Dormeasan, oral drops, solution (Valeriana officinalis L., radix, tincture; Humulus lupulus L., strobulus, tincture) Asp. No: 2008-1029 This module reflects
More informationLegal Requirements for the Control of Contaminants in Herbal Medicinal Products and Related Areas
Legal Requirements for the Control of Contaminants in Herbal Medicinal Products and Related Areas AOAC International Workshop Erlangen, 11 October 2011 Dr. Barbara Steinhoff Contents Heavy metals Microorganisms
More informationCOMMITTEE ON HERBAL MEDICINAL PRODUCTS (HMPC) FINAL COMMUNITY HERBAL MONOGRAPH ON AVENA SATIVA L., HERBA
European Medicines Agency Evaluation of Medicines for Human Use London, 4 September 2008 Doc. Ref. EMEA/HMPC/202966/2007 COMMITTEE ON HERBAL MEDICINAL PRODUCTS (HMPC) FINAL COMMUNITY HERBAL MONOGRAPH ON
More informationCOMMITTEE ON HERBAL MEDICINAL PRODUCTS (HMPC) FINAL
European Medicines Agency Evaluation of Medicines for Human Use London, 11 January 2007 Ref: EMEA/HMPC/182352/2005 Rev. 2 COMMITTEE ON HERBAL MEDICINAL PRODUCTS (HMPC) FINAL PROCEDURE FOR THE PREPARATION
More informationPublic Assessment Report Scientific discussion
Public Assessment Report Scientific discussion Hypermin, tablet [Hypericum perforatum L., (St. John s wort) herba recens, dry extract (3.1-4.0:1) ethanol 60 %] Asp. no: 2008-1034 This module reflects the
More informationCOMMITTEE ON HERBAL MEDICINAL PRODUCTS (HMPC) DRAFT COMMUNITY HERBAL MONOGRAPH ON EQUISETUM ARVENSE L., HERBA
European Medicines Agency Evaluation of Medicines for Human Use London, 31 October 2007 Doc. Ref. EMEA/HMPC/394894/2007 COMMITTEE ON HERBAL MEDICINAL PRODUCTS (HMPC) DRAFT COMMUNITY HERBAL MONOGRAPH ON
More informationPublic Assessment Report Scientific discussion. Ginsana, soft capsule. Asp.no.:
Läkemedelsverket 2014-04-15 Public Assessment Report Scientific discussion Ginsana, soft capsule (Panax ginseng C.A. Meyer, radix, standardised dry extract G115 Pharmaton (0.9-3.9:1, 40% ethanol)) Asp.no.:
More informationANNEX III ASEAN GUIDELINES ON LIMITS OF CONTAMINANTS FOR TRADITIONAL MEDICINES
Association of South East Asian Nations (ASEAN) ANNEX III ASEAN GUIDELINES ON LIMITS OF CONTAMINANTS FOR TRADITIONAL MEDICINES Disclaimer: This document is provided for information purpose only and subject
More informationDETERMINATION OF MICROBIAL CONTAMINANTS IN SOME MARKETED HERBAL FORMULATION
DETERMINATION OF MICROBIAL CONTAMINANTS IN SOME MARKETED HERBAL FORMULATION INTRODUCTION: Herbal medicines are in great demand in the developed as well as developing countries for primary health care because
More informationPublic Assessment Report Scientific discussion
Public Assessment Report Scientific discussion Helaflex, film-coated tablet (Harpagophytum procumbens (Burch) DC (devil s claw) dried root, dry extract (4.4-5.0:1) ethanol 60 %) SE/H/1561/01/MR This module
More informationPublic Assessment Report Scientific discussion
Public Assessment Report Scientific discussion Echinagard, oral drops, solution (Echinacea purpurea (L.) Moench, fresh herb, expressed juice (1.7-2.5:1)) Asp no: 2008-0658 This module reflects the scientific
More informationCOMMITTEE ON HERBAL MEDICINAL PRODUCTS (HMPC) FINAL COMMUNITY HERBAL MONOGRAPH ON ECHINACEA PALLIDA (NUTT.) NUTT., RADIX
European Medicines Agency Evaluation of Medicines for Human Use London, 16 July 2009 Doc. Ref.: EMEA/HMPC/332350/2008 COMMITTEE ON HERBAL MEDICINAL PRODUCTS (HMPC) FINAL COMMUNITY HERBAL MONOGRAPH ON ECHINACEA
More informationCOMMITTEE ON HERBAL MEDICINAL PRODUCTS (HMPC) FINAL COMMUNITY HERBAL MONOGRAPH ON SOLIDAGO VIRGAUREA L., HERBA
European Medicines Agency Evaluation of Medicines for Human Use London, 4 September 2008 Doc. Ref. EMEA/HMPC/285758/2007 COMMITTEE ON HERBAL MEDICINAL PRODUCTS (HMPC) FINAL COMMUNITY HERBAL MONOGRAPH ON
More informationPublic Assessment Report Scientific discussion. Echinaforce Forte, tablet. Asp. No:
Public Assessment Report Scientific discussion Echinaforce Forte, tablet Echinacea purpurea (L.) Moench (purple coneflower) herba recens, dry extract (17-34:1) and Echinacea purpurea (L.) Moench (purple
More informationEuropean Medicines Agency Evaluation of Medicines for Human Use COMMITTEE ON HERBAL MEDICINAL PRODUCTS (HMPC) FINAL
European Medicines Agency Evaluation of Medicines for Human Use London, 11 July 2008 Doc. Ref. EMEA/HMPC/513617/2006 COMMITTEE ON HERBAL MEDICINAL PRODUCTS (HMPC) FINAL COMMUNITY HERBAL MONOGRAPH ON HUMULUS
More informationCOMMITTEE ON HERBAL MEDICINAL PRODUCTS (HMPC) FINAL COMMUNITY HERBAL MONOGRAPH ON PASSIFLORA INCARNATA L., HERBA
European Medicines Agency Evaluation of Medicines for Human Use London, 7 September 2007 Doc. Ref: EMEA/HMPC/230962/2006 COMMITTEE ON HERBAL MEDICINAL PRODUCTS (HMPC) FINAL COMMUNITY HERBAL MONOGRAPH ON
More informationProf. Marina Heinonen University of Helsinki Member of the NDA Panel and EFSA s WG on Novel Foods
Guidance on Novel Foods Composition, production process and specification Prof. Marina Heinonen University of Helsinki Member of the NDA Panel and EFSA s WG on Novel Foods Info-Session 06 March 2017 Parma
More informationPublic Assessment Report Scientific discussion. Ginsana, oral solution. Asp.no.:
Läkemedelsverket 2014-04-15 Public Assessment Report Scientific discussion Ginsana, oral solution (Panax ginseng C.A. Meyer, radix, standardised dry extract G115 Pharmaton (0.9-3.9:1, 40% ethanol)) Asp.no.:
More informationEuropean Medicines Agency Evaluation of Medicines for Human Use. Superseded COMMITTEE ON HERBAL MEDICINAL PRODUCTS (HMPC) FINAL
European Medicines Agency Evaluation of Medicines for Human Use COMMITTEE ON HERBAL MEDICINAL PRODUCTS (HMPC) FINAL London, 3 July 2008 Doc. Ref. EMEA/HMPC/394894/2007 COMMUNITY HERBAL MONOGRAPH ON EQUISETUM
More informationREGISTRATION OF HERBAL AND COMPLEMENTARY PRODUCTS
REPUBLIC OF KENYA REGISTRATION OF HERBAL AND COMPLEMENTARY PRODUCTS GUIDELINES TO SUBMISSION OF APPLICATIONS PHARMACY AND POISONS BOARD PPB Copyright 2010 Page 1 of 16 PREFACE This guideline presents a
More informationMEDICNES CONTROL AGENCY GUIDELINE FOR REGISTRATION OF HERBAL MEDICINAL PRODUCTS IN THE GAMBIA
MEDICNES CONTROL AGENCY GUIDELINE FOR REGISTRATION OF HERBAL MEDICINAL PRODUCTS IN THE GAMBIA Document No.: MCA/HMPG/17/12/01 Date of Adoption: 20 th January 2017 Date of Issue: 25 th July 2017 Version
More informationCOMMITTEE ON HERBAL MEDICINAL PRODUCTS (HMPC) FINAL COMMUNITY HERBAL MONOGRAPH ON ALTHAEA OFFICINALIS L., RADIX
European Medicines Agency Evaluation of Medicines for Human Use London, 14 May 2009 Doc. Ref.: EMEA/HMPC/98717/2008 COMMITTEE ON HERBAL MEDICINAL PRODUCTS (HMPC) FINAL COMMUNITY HERBAL MONOGRAPH ON ALTHAEA
More informationEuropean Medicines Agency. Superseded COMMITTEE ON HERBAL MEDICINAL PRODUCTS (HMPC) FINAL COMMUNITY HERBAL MONOGRAPH ON SALVIA OFFICINALIS L.
European Medicines Agency COMMITTEE ON HERBAL MEDICINAL PRODUCTS (HMPC) FINAL London, 12 November 2009 Doc. Ref.: EMA/HMPC/331653/2008 COMMUNITY HERBAL MONOGRAPH ON SALVIA OFFICINALIS L., FOLIUM DISCUSSION
More informationEUROPEAN COMMISSION HEALTH AND FOOD SAFETY DIRECTORATE-GENERAL VOLUME 2C. Guidelines. Medicinal products for human use
EUROPEAN COMMISSION HEALTH AND FOOD SAFETY DIRECTORATE-GENERAL Brussels, March 2018 SANTE-2017-11668 Revision 2 NOTICE TO APPLICANTS VOLUME 2C Guidelines Medicinal products for human use Safety, environment
More informationOpinion on the safety assessment of phospholipds obtained from egg yolk as food produced using a new process
EUROPEAN COMMISSION DIRECTORATE-GENERAL XXIV CONSUMER POLICY AND CONSUMER HEALTH PROTECTION Directorate B - Scientific opinions on health matters Unit B3 - Management of scientific committees II SCIENTIFIC
More informationPublic Assessment Report. Scientific discussion. Pentasa Compact 4 g, prolonged-release granules. (mesalazine) NL License RVG:
Public Assessment Report Scientific discussion Pentasa Compact 4 g, prolonged-release granules (mesalazine) NL License RVG: 114015 Date: 30 March 2015 This module reflects the scientific discussion for
More informationon the approximation of the laws of the Member States concerning food additives authorized for use in foodstuffs intended for human consumption
11. 2. 89 Official Journal of the European Communities No L 40/ 27 COUNCIL DIRECTIVE of 21 December 1988 on the approximation of the laws of the Member States concerning food additives authorized for use
More informationEmanuela Turla Scientific Officer Nutrition Unit - EFSA
EFSA s role, experiences with the evaluation of the applications for authorisation of Novel Food or notification of Traditional Food from the third country Emanuela Turla Scientific Officer Nutrition Unit
More informationGuide to Registration of Homeopathic Veterinary Medicinal Products
Guide to Registration of Homeopathic Veterinary Medicinal Products AUT-G0047-3 16 NOVEMBER 2012 This guide does not purport to be an interpretation of law and/or regulations and is for guidance purposes
More informationGUIDANCE ON SUBMISSIONS FOR SAFETY EVALUATION OF SOURCES OF NUTRIENTS OR OF OTHER INGREDIENTS PROPOSED FOR USE IN THE MANUFACTURE OF FOODS
EUROPEAN COMMISSION HEALTH & CONSUMER PROTECTION DIRECTORATE-GENERAL Directorate C - Scientific Opinions C2 - Management of scientific committee; scientific co-operation and networks Scientific Committee
More informationPublic Assessment Report Scientific discussion. Prospan, oral solution (Hedera helix L. folium; dry extract (DER 5-7.
Public Assessment Report Scientific discussion Prospan, oral solution (Hedera helix L. folium; dry extract (DER 5-7.5:1); ethanol 30%) Asp. no: 2008-0572 This module reflects the scientific discussion
More informationThis document is meant purely as a documentation tool and the institutions do not assume any liability for its contents
1989L0107 EN 10.09.1994 001.001 1 This document is meant purely as a documentation tool and the institutions do not assume any liability for its contents B COUNCIL DIRECTIVE of 21December 1988 on the approximation
More informationStability Testing of Herbal Medicinal Products
Biopharma By Sven Oliver Kruse and Karim Sultan at Diapharm Stability Testing of Herbal Medicinal Products Particular legal requirements for quality control and stability studies of herbal medicinal products
More informationCOMMITTEE ON HERBAL MEDICINAL PRODUCTS (HMPC) FINAL
European Medicines Agency Evaluation of Medicines for Human Use London, 14 January 2009 Doc. Ref.: EMEA/HMPC/591648/2007 COMMITTEE ON HERBAL MEDICINAL PRODUCTS (HMPC) FINAL COMMUNITY HERBAL MONOGRAPH ON
More informationGuide. homoeopathic preparations. for the elaboration of monographs on
Guide for the elaboration of monographs on homoeopathic preparations " Stocks for homoeopathic preparations may be of mineral, chemical, botanical, zoological or human origin European Pharmacopoeia Homoeopathic
More informationGeneral concepts in the Ph. Eur.: theory and rationale
General concepts in the Ph. Eur.: theory and rationale Cathie VIELLE Head of European Pharmacopoeia Department, EDQM / CoE 1 The structure of the Ph. Eur. General monographs Dosage form monographs General
More informationIPEC Europe Suggested Alternative (if none then original text is clear and needs no alteration) Purpose and Scope
IPEC Europe Observations and Recommendations on Guidelines On The Formalised Risk Assessment For Ascertaining The Appropriate Good Manufacturing Practice For Excipients Of Medicinal Products For Human
More informationPublic Assessment Report Scientific discussion
Public Assessment Report Scientific discussion Harpatinum, capsule, soft Harpagophytum procumbens D.C. / H. zeyheri Decne (Devil s claw), radix, dry extract (4.4-5.0:1), ethanol 60 % (V/V) SE/H/1640/01/DC
More informationLIQUID PREPARATIONS FOR ORAL USE. Final text for addition to The International Pharmacopoeia (November 2007)
November 2007 LIQUID PREPARATIONS FOR ORAL USE Final text for addition to The International Pharmacopoeia (November 2007) This monograph was adopted at the Forty-second WHO Expert Committee on Specifications
More informationASEAN GUIDELINES ON LIMITS OF CONTAMINANTS FOR TRADITIONAL MEDICINES (TM) AND HEALTH SUPPLEMENTS (HS)
Association of South East Asian Nations (ASEAN) ASEAN GUIDELINES ON LIMITS OF CONTAMINANTS FOR TRADITIONAL MEDICINES (TM) AND HEALTH SUPPLEMENTS (HS) Version 3.0 CONTENTS 1. Introduction...2 2. Objective...
More informationPublic Assessment Report for a Traditional Herbal Medicinal Product for Human Use
IPAR Public Assessment Report for a Traditional Herbal Medicinal Product for Human Use Agnus castus oral drops Tincture of Agnus castus fruit TR2309/017/001 A. Vogel Ireland Limited 28 November 2018 CRN008R68
More information(Non-legislative acts) REGULATIONS
EN 17.2.2011 Official Journal of the European Union L 43/1 II (Non-legislative acts) REGULATIONS COMMISSION REGULATION (EU) No 137/2011 of 16 February 2011 amending Regulation (EC) No 2003/2003 of the
More informationSavesta Herbals is engaged in manufacturing
Savesta Herbals is engaged in manufacturing standardized herbal extracts that synergistically combine the ancient wisdom of Ayurveda with the modern production and QC methods. Our state-of- the- art production
More informationMEDICINES CONTROL COUNCIL
MEDICINES CONTROL COUNCIL COMPLEMENTARY MEDICINES - QUALITY, SAFETY, AND EFFICACY This guideline is intended to provide recommendations to applicants wishing to submit applications for the registration
More informationExpectations for Implementation in Europe
Expectations for Implementation in Europe Henk de Jong IPEC Federation Observer Q3D EWG PQRI/USP Workshop 3/31 & 4/1 2015 ICH Q3D is here CHMP (committee for Medicinal Products for Human Use) approved
More informationQuality control of herbal drug
Quality Assurance Unit Course Specification Assiut University Department of Faculty of Pharmacy Quality control of herbal drug Programme(s) on which the course is given: Bachelor of Pharmaceutical sciences
More informationCOMMISSION DIRECTIVE 97/48/ EC. of 29 July 1997
No L 222/ 10 r&ni Official Journal of the European Communities 12. 8. 97 COMMISSION DIRECTIVE 97/48/ EC of 29 July 1997 amending for the second time Council Directive 82/71 1/ EEC laying down the basic
More informationCOMMITTEE ON HERBAL MEDICINAL PRODUCTS (HMPC) DRAFT COMMUNITY HERBAL MONOGRAPH ON THYMUS VULGARIS L. AND THYMUS ZYGIS L., HERBA
European Medicines Agency Evaluation of Medicines for Human Use London, 8 May 2007 Doc. Ref. EMEA/HMPC/234113/2006 COMMITTEE ON HERBAL MEDICINAL PRODUCTS (HMPC) DRAFT COMMUNITY HERBAL MONOGRAPH ON THYMUS
More informationGuidance notes on the classification of food extracts with colouring properties Last update [ ]
DOES NOT NECESSARILY REPRESENT THE OFFICIAL VIEWS OF THE COMMISSION Guidance notes on the classification of food extracts with colouring properties Last update [28.10.2013] Contents 1. Purpose, definitions
More informationOfficial Journal of the European Union L 109/11
19.4.2008 Official Journal of the European Union L 109/11 COMMISSION REGULATION (EC) No 353/2008 of 18 April 2008 establishing implementing rules for applications for authorisation of health claims as
More informationPublic Assessment Report Scientific discussion
Public Assessment Report Scientific discussion Galexir, oral solution (Cynara scolymus (artichoke) dried leaf / Gentiana lutea (gentian) dried root /Curcuma longa (turmeric) dried rhizome, liquid extract,
More informationCOMMITTEE ON HERBAL MEDICINAL PRODUCTS (HMPC) FINAL
European Medicines Agency Evaluation of Medicines for Human Use London, 6 November 2008 Doc. Ref.: EMEA/HMPC/251323/2006 COMMITTEE ON HERBAL MEDICINAL PRODUCTS (HMPC) FINAL COMMUNITY HERBAL MONOGRAPH ON
More informationOfficial Journal of the European Union. (Non-legislative acts) REGULATIONS
22.8.2017 EN L 216/1 II (Non-legislative acts) REGULATIONS COMMISSION IMPLEMENTING REGULATION (EU) 2017/1490 of 21 August 2017 concerning the of manganous chloride tetrahydrate, manganese (II) oxide, manganous
More informationCOMMITTEE ON HERBAL MEDICINAL PRODUCTS (HMPC) FINAL COMMUNITY HERBAL MONOGRAPH ON AESCULUS HIPPOCASTANUM L., SEMEN
European Medicines Agency Evaluation of Medicines for Human Use London, 16 July 2009 Doc. Ref.: EMEA/HMPC/225319/2008 COMMITTEE ON HERBAL MEDICINAL PRODUCTS (HMPC) FINAL COMMUNITY HERBAL MONOGRAPH ON AESCULUS
More informationTECHNICAL REPORT OF EFSA. List of guidance, guidelines and working documents developed or in use by EFSA 1
EFSA Technical Report (2009) 279, 1-13 TECHNICAL REPORT OF EFSA List of guidance, guidelines and working documents developed or in use by EFSA 1 Prepared by the Secretariat of the Scientific Committee
More informationOVERVIEW OF COMMENTS RECEIVED ON COMMUNITY HERBAL MONOGRAPH ON HAMAMELIS VIRGINIANA L., FOLIUM (EMEA/HMPC/114586/2008)
European Medicines Agency Evaluation of Medicines for Human Use London, 12 November 2009 Doc. Ref.: EMA/HMPC/280729/2009 OVERVIEW OF COMMENTS RECEIVED ON COMMUNITY HERBAL MONOGRAPH ON HAMAMELIS VIRGINIANA
More informationCOMMITTEE ON HERBAL MEDICINAL PRODUCTS (HMPC) DRAFT COMMUNITY HERBAL MONOGRAPH ON VALERIANA OFFICINALIS L., RADIX AND HUMULUS LUPULUS L.
European Medicines Agency Evaluation of Medicines for Human Use London, 14 May 2009 Doc. Ref.: EMEA/HMPC/585558/2007 COMMITTEE ON HERBAL MEDICINAL PRODUCTS (HMPC) DRAFT COMMUNITY HERBAL MONOGRAPH ON VALERIANA
More informationUSP botanical quality standards: contributions in quality control & safe use of botanicals
USP botanical quality standards: contributions in quality control & safe use of botanicals Hellen Oketch-Rabah, PhD Senior Scientific Liaison, Dietary Supplements, Herbal Medicines UNITED STATES PHARMACOPEIA
More informationCOMMISSION DIRECTIVE 2011/3/EU
18.1.2011 Official Journal of the European Union L 13/59 DIRECTIVES COMMISSION DIRECTIVE 2011/3/EU of 17 January 2011 amending Directive 2008/128/EC laying down specific purity criteria on colours for
More informationThank you for your requests under the Freedom of Information Act Please find below responses to your questions.
Our reference: FOI/12-332 Dear Ms Mallinson Thank you for your requests under the Freedom of Information Act 2000. Please find below responses to your questions. 1. Please e-mail copies of the minutes
More informationGUIDE TO REGISTER HOMEOPATHIC PRODUCTS FOR VETERINARY USE
CAMEVET PROCEEDINGS II REVIEW DATE in BRAZIL: HOMEOPATHIC COMMISSION - SINDAN August 18, 2016 GUIDE TO REGISTER HOMEOPATHIC PRODUCTS FOR VETERINARY USE SÃO PAULO, BRAZIL August 2016 Page 2 of 9 GUIDE TO
More informationMEDICINES CONTROL COUNCIL
MEDICINES CONTROL COUNCIL COMPLEMENTARY MEDICINES - HEALTH SUPPLEMENTS QUALITY, SAFETY, EFFICACY This guideline is intended to provide recommendations to applicants wishing to submit applications for the
More information